Stay updated on Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial

Sign up to get notified when there's something new on the Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T22:28:37.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    5 days ago
    No Change Detected
  5. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of healthy volunteers included in a phase I/II trial for a trivalent influenza vaccine study. The change reflects an adjustment in the total number of participants involved in the evaluation of the GHB16L2 vaccine's safety and efficacy.
    Difference
    0.2%
    Check dated 2024-06-06T14:37:42.000Z thumbnail image
  6. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying the inclusion and exclusion criteria for healthy volunteers aged 18-60 years. Previously, no information was provided in this section.
    Difference
    26%
    Check dated 2024-05-22T21:02:04.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:23:17.000Z thumbnail image

Stay in the know with updates to Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial page.